How, if at all, has the new DAHANCA H&N contouring guidelines changed how you delineate low dose CTV (CTV-P2) for head and neck cancer primaries?

Should any additional anatomical areas be intentionally included in CTV-P2 if it goes beyond the "5+5" expansion? The text (found here:https://www.ncbi.nlm.nih.gov/pubmed/29180076) states that the PTV-P2 "may" or "likely" extend extend through certain structures but do not specify that these structures should be intentionally included if they go beyond the standard 10mm expansion. Are people in the US dropping anatomy based CTVs (eg for tonsil primaries - ipsilateral soft palate, ipsilateral base of the tongue, ipsilateral glossotonsillar sulcus. Superiorly, ipsilateral pharynx superiorly to pterygoid plate)? Do people stick with these recommendations only for T1/2 and not T3/4?